KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income (2016 - 2025)

Historic Net Income for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $690.0 million.

  • Teva Pharmaceutical Industries' Net Income rose 35090.91% to $690.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 25834.15%. This contributed to the annual value of $1.4 billion for FY2025, which is 17158.16% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Net Income stood at $690.0 million for Q4 2025, which was up 35090.91% from $432.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Net Income peaked at $690.0 million during Q4 2025, and registered a low of -$1.8 billion during Q4 2023.
  • In the last 5 years, Teva Pharmaceutical Industries' Net Income had a median value of -$43.5 million in 2021 and averaged -$217.8 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 128658.54% in 2022, then soared by 35090.91% in 2025.
  • Teva Pharmaceutical Industries' Net Income (Quarter) stood at -$151.0 million in 2021, then crashed by 783.44% to -$1.3 billion in 2022, then tumbled by 34.63% to -$1.8 billion in 2023, then surged by 84.69% to -$275.0 million in 2024, then skyrocketed by 350.91% to $690.0 million in 2025.
  • Its last three reported values are $690.0 million in Q4 2025, $432.0 million for Q3 2025, and $281.0 million during Q2 2025.